MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.
종목 코드 MIRA
회사 이름MIRA Pharmaceuticals Inc
상장일Aug 03, 2023
CEOAminov (Erez)
직원 수- -
유형Ordinary Share
회계 연도 종료Aug 03
주소1200 Brickell Avenue
도시MIAMI
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호33131
전화18133695150
웹사이트https://mirapharmaceuticals.com/
종목 코드 MIRA
상장일Aug 03, 2023
CEOAminov (Erez)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음